Browse by author
Lookup NU author(s): Dr Mark Verrill
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose. Deep fibromatoses are large, often rapidly growing but benign soft tissue tumours. Although surgery is the mainstay of treatment, in unremitting and aggressive cases the use of cytotoxic chemotherapy may produce objective tumour responses. Fresh turnout samples from four patients with fibromatosis were investigated as part of a study of drug resistance in soft tissue tumours. Methods. Following short-term culture of fibromatosis cells in vitro, chemosensitivity to 4-hydroperoxy-ifosfamide, the active form of ifosfamide and doxorubicin was tested. Following 72-h continuous exposure to each drug, surviving cell fraction was assessed using the lactate dehydrogenase assay. Results. Mean IC50 values for ifosfamide and doxorubicin were 6.2 and 0.35 μmol/l, respectively. In samples of soft tissue sarcoma (STS) from the same study the mean IC50 values for ifosfamide and doxorubicin were 14.8 and 1.69 μmol. The difference in mean ifosfamide IC50 values for fibromatosis and STS samples was statistically significant. Discussion. We are not aware of any other report suggesting the use of ifosfamide in this condition. These observations suggest that, for patients with inoperable or progressive lesions of fibromatosis causing significant morbidity, it may be valuable to include ifosfamide in experimental treatment regimens.
Author(s): Verrill MW, Coley HM, Judson IR, Fisher C
Publication type: Article
Publication status: Published
Journal: Sarcoma
Year: 1999
Volume: 3
Issue: 2-3
Pages: 79-84
Print publication date: 01/01/1999
ISSN (print): 1357-714X
ISSN (electronic): 1369-1643
Publisher: Hindawi Publishing Corporation
URL: http://dx.doi.org/10.1080/13577149977686
DOI: 10.1080/13577149977686
Altmetrics provided by Altmetric
